| Patient | Srinivasa Ramanujan |
|---|---|
| Date of birth | 1996-12-22 |
| Identifiers | MRN HR-ET020-SYN; SSN (made up) 000-20-1937 |
| Document date | 2026-04-20 |
| Author | Edmund Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three months: abscess treatment complete, rifampin month two, blood count, liver tests, vitamins, mood, and plans to visit home. [S]
Mr. Ramanujan returns two weeks after his preventive visit. He has had no fever, pain, night sweats or diarrhea since the cold a month ago, and his weight is close to what it was before he fell ill. He is two months into rifampin, with no missed doses, nausea, rash or yellowing. He takes vitamin B12 and vitamin D daily. His hepatitis A antibody was positive, so he needs no vaccine for the trip, and the travel clinic has given him advice on malaria and food. He still sees the counselor, now every two weeks, calls home each Sunday, and has offered to teach a mathematics class at the Tamil association. He leaves for India in the summer and will take enough rifampin to finish the course there. [S]
| Element | Detail |
|---|---|
| Symptoms | None |
| Rifampin | Two months of four; no side effects |
| Travel | Hepatitis A immune; travel clinic seen; typhoid vaccine given |
| Mood | PHQ-9 5 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or sweats; weight nearly back to before the illness |
| Gastrointestinal | Negative | No pain, nausea or diarrhea |
| Eyes | Negative | Orange tears only; no yellowing |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Mood much better; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metronidazole 250 mg oral tablet, three tablets (750 mg) three times a day with food for 10 days | Three tablets every 8 hours with food for 10 days | Oral route | 2026-01-14 to 2026-01-23 | completed | S |
| Paromomycin 250 mg oral capsule, two capsules (500 mg) three times a day with meals for 7 days, started the day after metronidazole ends | Two capsules every 8 hours with meals for 7 days | Oral route | 2026-01-24 to 2026-01-30 | completed | S |
| Vitamin B12 (cyanocobalamin) 1,000 microgram oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-14 | active | S |
| Cholecalciferol 50,000 unit (1.25 mg) oral tablet, one tablet once a week for 8 weeks | One tablet once a week for 8 weeks | Oral route | 2026-01-14 to 2026-03-04 | completed | S |
| Cholecalciferol 2,000 unit (50 microgram) oral tablet, one tablet daily, from the end of the weekly course | One tablet daily | Oral route | 2026-03-05 | active | S |
| Rifampin 300 mg oral capsule, two capsules (600 mg) once daily on an empty stomach for 4 months | Two capsules each morning before breakfast for 4 months | Oral route | 2026-02-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-20 | Body height | 165 | cm | S |
| 2026-04-20 | Body weight | 56.6 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 20.8 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 70 | /min | S |
| 2026-04-20 | Respiratory rate | 14 | /min | S |
| 2026-04-20 | Body temperature | 36.6 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-20 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-04-20 | Hemoglobin [Mass/volume] in Blood | 13.8 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 2026-04-20 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 90 | fL | 80-100 fL | Normal | S |
| 2026-04-20 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-20 | C reactive protein [Mass/volume] in Serum or Plasma | 2 | mg/L | <=5 mg/L | Normal | S |
| 2026-04-20 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 40-129 U/L | Normal | S |
| 2026-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-41 U/L | Normal | S |
| 2026-04-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 10-40 U/L | Normal | S |
| 2026-04-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-04-20 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 520 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-04-20 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 32 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-04-20 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | {score} | S |
Vital signs recorded on 2026-04-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; temperature 36.6 °C, pulse 70; weight 56.6 kg |
| Abdomen | Liver not enlarged or tender |
| Skin | No rash or jaundice |
| Psychiatric | Warm and engaged; smiles when he talks about the class he will teach |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Evening fevers to 38.6 °C with night sweats for about four weeks | resolved | confirmed | R50.9 | S — Synthetic presenting symptom, superseded by the diagnosis at the second visit. |
| Weight loss of 5 kg over two months (57 to 52 kg), with poor appetite | resolved | confirmed | R63.4 | S — Synthetic presenting symptom, superseded by the diagnosis at the second visit. |
| Dull right upper quadrant pain for three weeks, worse on deep breathing and lying on the right side, with a tender liver edge | resolved | confirmed | R10.11 | S — Synthetic presenting symptom, superseded by the diagnosis at the second visit. |
| Amebic liver abscess: a single 6.2 x 5.4 cm abscess in the right lobe (segment VII) on ultrasound, Entamoeba histolytica antibody positive, blood cultures negative, years after two episodes of dysentery in India; treated with metronidazole and then paromomycin; synthetic modern diagnosis linked to the hepatic amoebiasis later proposed for his illness | resolved | confirmed | A06.4 | S — Synthetic modern diagnosis; it does not settle the historical diagnostic conflict (CLM-0010, CLM-0011). |
| Vitamin B12 deficiency from a strict vegetarian diet (B12 168 pg/mL), with anemia (hemoglobin 11.2 g/dL, MCV 99 fL) to which inflammation also contributes | active | confirmed | D51.3 | S — Synthetic finding anchored to his documented diet and the vitamin deficiency later proposed. |
| Vitamin D deficiency (25-hydroxyvitamin D 9 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding anchored to his documented diet and the vitamin deficiency later proposed. |
| Positive interferon-gamma release assay, with chest radiograph and sputum smears and NAAT negative for tuberculosis; cultures pending | resolved | confirmed | R76.12 | S — Synthetic finding, superseded by the diagnosis of latent infection when cultures were negative. |
| Latent tuberculosis infection: positive interferon-gamma release assay, normal lungs on the radiograph, three sputum smears, NAAT and cultures negative; treated with four months of rifampin | active | confirmed | Z22.7 | S — Synthetic modern diagnosis; active tuberculosis was excluded, which does not settle the historical question. |
| Adjustment disorder with depressed mood (PHQ-9 12, no thoughts of self-harm) during a serious illness, far from his wife and family | active | confirmed | F43.21 | S — Synthetic modern diagnosis anchored to his documented loneliness; not a claim about his real mental health. |
| Acute viral upper respiratory infection, three weeks into rifampin and six weeks after treatment of the liver abscess, without signs of abscess relapse; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Temperature, symptoms and abdominal examination (liver tenderness, right lower rib tenderness) | Every visit | Completed today | No fever; liver not tender |
| Examination | Weight and BMI | Every visit | Completed today | 56.6 kg, up 4.6 kg since intake |
| Laboratory | Blood count and C-reactive protein | At diagnosis, at the end of the tissue course, then until normal | Completed today | White cells 6.2, hemoglobin 13.8, MCV 90, platelets 262; CRP 2 mg/L |
| Laboratory | Liver tests (alkaline phosphatase, ALT, AST, bilirubin, albumin) | At diagnosis, at the end of therapy, and before and during rifampin | Completed today | Alkaline phosphatase 96, ALT 30, AST 26 U/L, bilirubin 0.7 mg/dL on rifampin |
| Imaging | Liver imaging | At diagnosis; repeat only for no response or a complication | Not indicated | Recovered; no repeat imaging |
| Medication safety | Rifampin safety and adherence (nausea, rash, jaundice, missed doses, drug interactions) | Monthly clinical check; liver tests at baseline and as indicated | Completed today | Two months; no missed doses or side effects; supply for travel arranged |
| Laboratory | Response to vitamin B12 replacement | Reticulocyte count at 1 week; blood count at about 8 weeks; neurologic examination at diagnosis | Completed today | Blood count normal at about three months; B12 520 pg/mL |
| Laboratory | 25-hydroxyvitamin D | At diagnosis; after repletion | Completed today | 32 ng/mL after repletion |
| Self-management | Diet and weight plan within his vegetarian rules | Every visit | Completed today | Two meals a day within his rules; weight nearly regained |
| Survey | PHQ-9 and GAD-7 | At least monthly while symptoms are active | Completed today | PHQ-9 5, GAD-7 4 |
| Survey | Suicide-risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; a crisis contact for India added to the safety plan for the trip |
| Self-management | Support far from home (counseling, contact with family and community, department and fellowship) | Every visit | Completed today | Counseling every two weeks; calls home; teaching a class in his community |
Goal progress:
Guideline basis: Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 (2020); DPDx: Amebiasis (laboratory diagnosis, including antibody detection in extraintestinal disease) (2026); A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis (2018); Position of the Academy of Nutrition and Dietetics: Vegetarian Diets (2016); CMID: Clinical Monitoring Intelligence Database, anemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Second hepatitis B dose before he travels. Completion of rifampin, by video from India if needed. Review on his return with vitamin D, a lipid panel and mood. Seek care promptly for fever or right-sided pain while away. [S]